Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.

Andrew S ChiRohinton S TaraporeMatthew D HallNicole ShonkaSharon GardnerYoshie UmemuraAshley SumrallZiad KhatibSabine MuellerCassie KlineWafik ZakySoumen KhatuaShiao-Pei WeathersYazmin OdiaToba N NiaziDoured DaghistaniIrene CherrickDavid KoronesMatthias A KarajannisXiao-Tang KongJane MinturnAngela WaandersIsabel Arillaga-RomanyTracy BatchelorPatrick Y WenKrystal MerdingerLee SchalopMartin StogniewJoshua E AllenWolfgang OsterMinesh P Mehta

Published in: Journal of neuro-oncology (2019)

The clinical outcomes and radiographic responses in these patients provide the preliminary, and initial clinical proof-of-concept for targeting H3 K27M-mutant diffuse midline glioma with ONC201, regardless of age or location, providing rationale for robust clinical testing of the agent.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
low grade
prognostic factors
clinical trial
cancer therapy
patient reported outcomes
high grade